111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity

European Journal of Cancer

Volumn 43, Issue 14, 2007, Pages 2046-2051

  de Korte, M A ^a   de Vries, E G E ^a   Lub de Hooge, M N ^a   Jager, P L ^a   Gietema, J A ^a   van der Graaf, W T A ^a   Sluiter, W J ^a   van Veldhuisen, D J ^a   Suter, T M ^b   Sleijfer, D T ^a   Perik, P J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Breast cancer; Cardiotoxicity; HER2; Molecular imaging; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; IFOSFAMIDE; PENTETATE INDIUM IN 111; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; PENTETIC ACID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; EWING SARCOMA; FEMALE; HEART FAILURE; HEART MUSCLE; HEART SCINTISCANNING; HEART STRESS; HUMAN; IMAGE ANALYSIS; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; HEART DISEASE; METABOLISM; METHODOLOGY; MIDDLE AGED; NEOPLASM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; FEMALE; HEART DISEASES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NEOPLASMS; PENTETIC ACID; RECEPTOR, ERBB-2; STRESS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; UP-REGULATION;

EID: 34548481766     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.06.024     Document Type: Article

References (17)

1. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
2. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1659-1672
3. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
4. Slamon D, Eiermann W, Robert N, et al., Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study, Proc San Antonio Breast Cancer Symposium, 2005 [abstract #1].
5. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 31 (2005) 7811-7819
6. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 8 (2006) 809-820
7. Chien K.R. Herceptin and the heart - a molecular modifier of cardiac failure. N Engl J Med 354 8 (2006) 789-790
8. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339 13 (1998) 900-905
9. Kuramochi Y., Cote G.M., Guo X., et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem 279 49 (2004) 51141-51147
10. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23 31 (2005) 7820-7826
11. Ewer M.S., and Lippman S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23 13 (2005) 2900-2902
12. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8 5 (2002) 459-465
13. Ozcelik C., Erdmann B., Pilz B., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 99 13 (2002) 8880-8885
14. Fuchs I.B., Landt S., Bueler H., et al. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Breast Cancer Res Treat 82 1 (2003) 23-28
15. Lub-De Hooge M.N., Kosterink J.G., Perik P.J., et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 143 1 (2004) 99-106
16. Perik P.J., Lub-De Hooge M.N., Gietema J.A., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24 15 (2006) 2276-2282
17. Uray I.P., Connelly J.H., Thomazy V., et al. Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transpl 21 7 (2002) 771-782